Evgen Pharma PLC Posting of Annual Report and AGM Notice (1666S)
21 June 2018 - 9:30PM
UK Regulatory
TIDMEVG
RNS Number : 1666S
Evgen Pharma PLC
21 June 2018
For immediate release 21 June 2018
Evgen Pharma plc
("Evgen" or "the Company")
Posting of Annual Report and AGM Notice
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, announces that its Annual Report and Accounts for the
year ending 31 March 2018 together with the notice of Annual
General Meeting ("AGM") have today been posted to shareholders.
The documents are being made available at the investor relations
section of the Company's website, www.evgen.com.
The Company's AGM will be held at 2.00pm at the offices of RSM
UK Audit LLP, 3 Hardman Street, Manchester M3 7HF on Thursday 26
July 2018.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Wills, Tilly Abraham +44 (0) 20 7466 5000
Northland Capital Partners Limited
Matthew Johnson, Tom Price, Gerry Beaney
(Corporate Finance)
John Howes, Rob Rees (Corporate Broking) +44 (0) 20 3861 6625
Notes for editors:
About Evgen Pharma plc
Evgen is a clinical stage drug development company whose lead
programmes are in breast cancer and subarachnoid haemorrhage, a
type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACSFFLFLVQFLBBX
(END) Dow Jones Newswires
June 21, 2018 07:30 ET (11:30 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024